Skip to main content

European Med Tech Market Access Services for Pharma

Your Preferred Specialized Vendor in Niche and Complex Area of Medical Devices

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Governmental plans announced to abolish the NHS England

On March 13, 2025, the Department of Health and Social Care (DHSC) unveiled a major organizational reform, announcing plans to abolish NHS England by bringing it back under DHSC. This reform will reverse the 2012 top-down restructuring of the NHS. 

The primary objectives of this change are to reduce complex bureaucracy, eliminate overlapping functions between NHS England and the DHSC, enhance efficiency, and empower staff to deliver better care as part of Prime Minister’s Plan for Change. Additionally, the reform is expected to yield significant cost savings.

These reforms will support the three key shifts identified by the government as vital to creating an NHS fit for the future: analogue to digital, sickness to prevention and hospital to community.

The process of returning many of NHS England’s functions to the DHSC will begin immediately, with the full transition expected to be completed within two years.

See the full details here and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.